Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-12323 in symptomatic moderate to severe asthma
ACTRN12607000192482Phase 2Not yet recruiting
- Sponsor
- Epigenesis Pharmaceuticals
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in asthma comparing EPI-12323 + budesonide with Placebo + budesonide (2 arms). Primary endpoint: Asthma control. Planned start Jun 2007; status: not yet recruiting.
02
Drugs
EPI-12323
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12607000192482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000192482.